What is Infant Bacterial Therapeutics AB (publ)'s (IBT-B.ST) StockRank?

MoatMap's StockRank for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is 18/100, with a Strong Sell signal. This is a composite score combining Quality (24), Value (23), and Momentum (60) factor ranks across MoatMap's 19,000+ stock universe.

Does Infant Bacterial Therapeutics AB (publ) have an economic moat?

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Infant Bacterial Therapeutics AB (publ) a buy, hold, or sell?

MoatMap's current signal for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Infant Bacterial Therapeutics AB (publ) in?

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) operates in the Healthcare sector, specifically the Biotechnology industry (Sweden).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IBT-B.ST

STRONG SELLREMOVE

Infant Bacterial Therapeutics AB (publ) · Healthcare · Sweden · $82M · Avg Vol: $98K/d

StockRank

P/E (TTM)

—

ROE

-60.5%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Infant Bacterial Therapeutics is a clinical-stage biotech with no commercialized products or recurring revenues, failing our quality and cash-flow requirements.

COMPANY DESCRIPTION

Infant Bacterial Therapeutics AB is a clinical-stage pharmaceutical company focused on developing therapies to prevent life-threatening diseases in premature infants. Its lead candidate, IBP-9414, is a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC), a devastating disease with no current approved treatments. The company holds Orphan Drug Designation in both the US and Europe, providing significant market exclusivity and regulatory protection upon commercialization.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.63	-1.08	-1.10	-0.53	—
Shares	11M	13M	13M	13M	+20.0%
Debt	2M	5M	8M	6M	46.6%
Equity	36M	33M	18M	11M	-31.8%
Op CF	-9M	-11M	-12M	-8M	—
Inv CF	—	0	0	—	—
Fin CF	204,511	10M	218,514	0	—

PRICE (1M)+22.6%

SMA 50SMA 200

$7.18

RSI (14)

87.2

52W High

$9.15

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-65.5%9.5

ROE

-60.5%14.3

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-22.3%14.9

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

2.23x41.7

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

10.7x9.7

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

78%71.4

RS 6M

40%93.0

SMA 50/200

0.99x58.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$82M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IBT-B.ST are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
IBT-B.ST	Infant Bacterial Therapeutics AB (publ)(you)	$82M	18	STRONG SELL
ONCO.ST	Oncopeptides AB (publ)	$76M	6	STRONG SELL
SYNACT.ST	SynAct Pharma AB	$102M	7	STRONG SELL
MVIR.ST	Medivir AB (publ)	$118M	27	SELL
XSPRAY.ST	Xspray Pharma AB (publ)	$126M	5	STRONG SELL
BINV.ST	BioInvent International AB (publ)	$239M	20	STRONG SELL
FLERIE.ST	Flerie AB (publ)	$242M	23	SELL
EGTX.ST	Egetis Therapeutics AB (publ)	$297M	22	SELL
VICO.ST	Vicore Pharma Holding AB (publ)	$356M	15	STRONG SELL
GENO.ST	Genovis AB (publ.)	$144M	48	HOLD

Peer medians: ROE 5.1% · P/E 37.9x · Gross margin 62.3%

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) — Stock Score Summary

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) has a MoatMap StockRank of 18/100 based on Quality (24/100), Value (23/100), and Momentum (60/100) factor scores. The current signal is STRONG SELL. Infant Bacterial Therapeutics is a clinical-stage biotech with no commercialized products or recurring revenues, failing our quality and cash-flow requirements.

Key Financial Metrics

Price	$7.18
Market Cap	$82M
Price/Book	10.67
Return on Equity	-60.5%
Return on Invested Capital	-65.5%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-419K

Infant Bacterial Therapeutics AB (publ) operates in the Biotechnology industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Infant Bacterial Therapeutics AB (publ)’s (IBT-B.ST) StockRank?: MoatMap’s StockRank for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is 18/100, with a Strong Sell signal. It is a composite of Quality (24), Value (23), and Momentum (60) factor ranks across MoatMap’s 19,000+ stock universe.
Does Infant Bacterial Therapeutics AB (publ) have an economic moat?: Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Infant Bacterial Therapeutics AB (publ) a buy, hold, or sell?: MoatMap’s current signal for Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Infant Bacterial Therapeutics AB (publ) in?: Infant Bacterial Therapeutics AB (publ) (IBT-B.ST) operates in the Healthcare sector, specifically the Biotechnology industry (Sweden).